The phase I COBALT-RCC trial, which assessed CD70-targeted CAR-T cells in heavily pretreated ccRCC, reported a disease control rate (DCR) of 81%, indicating that CAR therapy may play a role in overcoming ICI/TKI treatment resistance [200]. Here, CD70 is linked to renal cell carcinoma.